Dopamine-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) plays a central role in medium spiny neurons in the neostriatum in the integration of various neurotransmitter signaling pathways. In its Thr-34-phosphorylated form, it acts as a potent protein phosphatase-1 inhibitor, and, in its Thr-75-phosphorylated form, it acts as a cAMP-dependent kinase inhibitor. Here, we investigated glutamate-dependent signaling cascades in mouse neostriatal slices by analyzing the phosphorylation of DARPP-32 at Thr-34 and Thr-75. Treatment with glutamate (5 mM) caused a complex change in DARPP-32 Thr-34 phosphorylation. An initial rapid increase in Thr-34 phosphorylation was NMDA͞␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)͞metabo-tropic glutamate-5 receptor-dependent and was mediated through activation of a neuronal nitric oxide synthase͞nitric oxide͞cGMP͞ cGMP-dependent kinase signaling cascade. A subsequent decrease in phosphorylation was attributable to activation of an NMDA͞ AMPA receptor͞Ca 2؉ ͞protein phosphatase-2B signaling cascade. This decrease was followed by rephosphorylation via a pathway involving metabotropic glutamate-5 receptor͞phospholipase C and extracellular receptor kinase signaling cascade. Treatment with glutamate initially decreased Thr-75 phosphorylation through activation of NMDA͞AMPA receptor͞Ca 2؉ ͞protein phosphatase-2A signaling. Thereafter, glutamate slowly increased Thr-75 phosphorylation through activation of metabotropic glutamate-1 receptor͞phospholipase C signaling. Our analysis of DARPP-32 phosphorylation in the neostriatum revealed that glutamate activates at least five different signaling cascades with different time dependencies, resulting in complex regulation of protein kinase and protein phosphatase activities.
D
ARPP-32, a dopamine-and cAMP-regulated phosphoprotein of 32 kDa, is a signal transduction molecule that is selectively enriched in medium spiny neurons in the neostriatum (1) . Mice lacking DARPP-32 exhibit profound deficits in their molecular, electrophysiological, and behavioral responses to dopamine, drugs of abuse, and antipsychotic medication (2) , indicating an essential role for DARPP-32 in dopamine signaling. DARPP-32 is phosphorylated at Thr-34 by cAMP-dependent protein kinase (PKA), resulting in its conversion into a potent inhibitor of protein phosphatase-1 (PP-1). DARPP-32 is phosphorylated at Thr-75 by cyclin-dependent kinase 5 (Cdk5) (3) . DARPP-32 phosphorylated at Thr-75 inhibits PKA activity and thereby reduces the efficacy of dopamine signaling. Dopamine, by means of dopamine D1 receptors, activates PKA, which directly stimulates DARPP-32 Thr-34 phosphorylation and indirectly stimulates DARPP-32 Thr-75 dephosphorylation (4, 5) . By regulating the activity of PKA and PP-1, dopamine controls the state of phosphorylation of various intracellular targets.
Glutamate is the major excitatory neurotransmitter in the brain. The excitation of medium spiny neurons is regulated by a balance of glutamatergic inputs from corticostriatal and thalamostriatal pathways and dopaminergic inputs from the nigrostriatal pathway (6, 7) . Through the use of various selective agonists and antagonists, glutamate receptor activation has been shown to modulate dopaminergic signaling. Several different signal transduction pathways initiated by NMDA͞␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and metabotropic glutamate (mGlu) receptors have been described. Activation of NMDA and AMPA receptors decreases DARPP-32 phosphorylation at Thr-34 and Thr-75 through Ca 2ϩ -dependent activation of protein phosphatase-2B (PP-2B) (calcineurin) and protein phosphatase-2A (PP-2A), respectively (8) . Activation of group I mGlu-5 (mGlu5) receptors increases DARPP-32 Thr-34 phosphorylation by potentiating cAMP formation coupled to adenosine A 2A receptors in an extracellular signal-regulated kinase (ERK)-dependent manner (9) . Activation of group I mGlu receptors also increases DARPP-32 phosphorylation at Thr-75 as well as Ser-130 [casein kinase-1 (CK1)-site] (10). Group I mGlu receptors stimulate phospholipase C (PLC) and CK1 (11) , resulting in activation of Cdk5 by an unknown mechanism, leading to phosphorylation of Thr-75. However, the signal transduction pathways mediating the biological effects of glutamate per se have not received much attention. Here, we have investigated the effects of various signaling pathways, activated by glutamate, on the phosphorylation of DARPP-32 at Thr-34 and Thr-75.
Materials and Methods
Preparation and Incubation of Striatal Slices. Neostriatal slices were prepared from male C57BL͞6 mice (6-8 weeks old), as described in ref. 8 . Slices were treated with drugs as specified in each experiment, and the following drugs were obtained: glutamate, MK-801, and SCH23390 from Sigma; 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), LY367385, 2-methyl-6-(phenylethynyl)pyridine (MPEP), 7-nitroindazole monosodium salt (7-NINA), 1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ), U0126, U73122, and ZM241385 from Tocris Cookson (Bristol, U.K.); and calyculin A, cyclosporin A, and okadaic acid from LC Laboratories (Woburn, MA). After drug treatment, slices were transferred to Eppendorf tubes, frozen on dry ice, and stored at Ϫ80°C until assayed.
Immunoblotting. Frozen tissue samples were sonicated in boiling 1% SDS. Equal amounts of protein (100 g) were processed by using 12% acrylamide gels as described in ref. 8 
. Immunoblotting
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was carried out by using a monoclonal antibody raised against a DARPP-32 peptide containing phospho-Thr-34, the site phosphorylated by PKA (mAb-23; 1:750 dilution) (30) , and an affinitypurified polyclonal antibody raised against a DARPP-32 peptide containing phospho-Thr-75, the site phosphorylated by Cdk5 (1:6,000 dilution) (3). A monoclonal antibody (C24-5a; 1:7,500 dilution) generated against DARPP-32 (12), which is not phosphorylation state-specific, was used for reblotting the membranes to determine the total amount of DARPP-32 in samples. None of the experimental manipulations used in the present study altered the total amount of DARPP-32.
In some experiments, the membranes were immunoblotted by using an affinity-purified antibody that selectively detected the phosphorylated form of neuronal nitric oxide synthase (nNOS) at Ser-847 (1:500 dilution) (13) and then were reblotted by using an nNOS antibody (Santa Cruz Biotechnology) (1:2,000 dilution).
Antibody binding was detected by the ECL immunoblotting detection system (Amersham Pharmacia). Phospho-DARPP-32 and phospho-nNOS bands were quantified by densitometry using NIH IMAGE 1.61 software (http:͞͞rsb.info.nih.gov͞nih-image͞). Samples from control and drug-treated slices were routinely analyzed on individual immunoblots. For each experiment, values obtained for treated slices were calculated relative to the value for the control slices. Normalized data from multiple experiments were averaged, and statistical analysis was carried out by using one-way ANOVA and Newman-Keuls test, unless specified.
Results

Effect of Glutamate on DARPP-32 Phosphorylation at Thr-34 and
Thr-75 in Neostriatal Neurons. Treatment of neostriatal slices with glutamate (5 mM) rapidly increased the level of phospho-Thr-34 DARPP-32 by 3.5-fold within 15 s of incubation (Fig. 1A) . The increase in DARPP-32 Thr-34 phosphorylation was transient, and phosphorylation returned to the basal level at 1 min of incubation. At 2 and 5 min of incubation time, the level of phospho-Thr-34 DARPP-32 had a tendency to be below the basal level, but the decrease was not statistically significant. Treatment with glutamate (5 mM) decreased the level of phospho-Thr-75 DARPP-32 to 60% of control by 5 min of incubation. The level of phospho-Thr-75 DARPP-32 returned to the basal level at 10 min of incubation.
Role of Ionotropic and mGlu Receptors in the Regulation of DARPP-32
Phosphorylation. To investigate the role of ionotropic NMDA and AMPA receptors, the effect of glutamate was examined in the presence of an NMDA receptor antagonist, MK801 (100 M); an AMPA receptor antagonist, CNQX (20 M); or MK801 plus CNQX ( Fig. 1 B-D) . Pretreatment with MK801, CNQX, or MK801 plus CNQX did not affect the basal level of phosphoThr-34 DARPP-32 but abolished the glutamate-induced, rapid increase in DARPP-32 Thr-34 phosphorylation (15-to 30-s incubation) and the glutamate-induced tendency to decrease Thr-34 phosphorylation below the basal level at 2 and 5 min of incubation. Furthermore, in the presence of MK801 alone or MK801 plus CNQX, glutamate increased the level of phosphoThr-34 DARPP-32 at 10 min of incubation by 3-or 4-fold, respectively. In the presence of CNQX, glutamate slightly increased the level of phospho-Thr-34 DARPP-32 at 10 min of incubation, but the effect was not statistically significant. These results suggest that the rapid increase and the subsequent decrease in DARPP-32 Thr-34 phosphorylation induced by glutamate is mediated through activation of NMDA and AMPA receptors. The results also revealed a third delayed phase of glutamate-dependent signaling that was masked by the actions of NMDA and AMPA receptor activation.
Pretreatment with MK801, CNQX, or MK801 plus CNQX did not affect the basal level of phospho-Thr-75 DARPP-32 but abolished the glutamate-induced decrease in Thr-75 phosphorylation. In the presence of MK801 or MK801 plus CNQX, glutamate (5 mM) increased the level of phospho-Thr-75 DARPP-32 by 2-fold at 5 and 10 min of incubation. These results suggest that the decrease in DARPP-32 Thr-75 phosphorylation induced by glutamate is mediated through activation of NMDA and AMPA receptors.
To identify mGlu receptors involved in the regulation of DARPP-32 Thr-34 and Thr-75 phosphorylation by glutamate, the effect of glutamate was examined in the presence of an mGlu5 receptor antagonist, MPEP (10 M); an mGlu1 receptor antagonist, LY341495 (100 M); or MPEP plus LY367385 (compare Fig.  2 with Fig. 1 A) . Pretreatment with MPEP, LY341495, or MPEP plus LY341495 did not affect the basal level of phospho-Thr-34 or phospho-Thr-75 DARPP-32. Pretreatment with MPEP or with MPEP plus LY341495, but not LY341495, abolished the rapid increase in DARPP-32 Thr-34 phosphorylation induced by glutamate. Pretreatment with MPEP and͞or LY341495 did not affect the glutamate-induced decrease in Thr-75 phosphorylation.
We next examined the role of mGlu receptors on the glutamateinduced regulation of DARPP-32 Thr-34 and Thr-75 phosphory- lation, when glutamate effects on both NMDA and AMPA receptors were blocked (Fig. 3) . The glutamate-induced increase in Thr-34 phosphorylation observed in the presence of MK801 plus CNQX was attenuated by MPEP (10 M) (two-way ANOVA, P Ͻ 0.01). LY341495 (100 M) slightly attenuated the delayed increase in Thr-34 phosphorylation, but the effect was not statistically significant. These results suggest that mGlu5 receptors are involved in glutamate-induced regulation of DARPP-32 Thr-34 phosphorylation in two ways: (i) a rapid increase in Thr-34 phosphorylation and (ii) a delayed increase in Thr-34 phosphorylation that is counteracted by the effects of NMDA and AMPA receptors.
The glutamate-induced increase in Thr-75 phosphorylation in the presence of MK801 plus CNQX was attenuated by LY341495 (100 M) (two-way ANOVA, P Ͻ 0.01) but was not affected by MPEP (10 M). Thus, under these conditions, activation of mGlu1 receptors by glutamate stimulates the phosphorylation of DARPP-32 at Thr-75.
Role of ERK and PLC␤ Signaling in mGlu Receptor-Mediated Regulation of DARPP-32 Phosphorylation. To further investigate the mechanism by which mGlu5 and mGlu1 receptors regulate DARPP-32 phosphorylation, the effects of an ERK inhibitor, U0126, and a PLC␤ inhibitor, U73122, were examined on the glutamate-induced increase in DARPP-32 Thr-34 and Thr-75 phosphorylation in the presence of MK801 and CNQX (Fig. 4) . Both U0126 (40 M) and U73122 (25 M) attenuated the stimulatory effect of glutamate on Thr-34 phosphorylation. In contrast, the stimulatory effect of glutamate on Thr-75 phosphorylation was attenuated by U73122 but not U0126. These results, together with those presented in Fig.  3 , suggest that the delayed increase in Thr-34 phosphorylation is mediated through PLC␤ and ERK signaling, activated by mGlu5 receptors, and that the delayed increase in Thr-75 phosphorylation is mediated through PLC␤ signaling, activated by mGlu1 receptors.
Role of nNOS͞NO͞cGMP͞cGMP-Dependent Protein Kinase (PKG) Signaling in Glutamate-Induced Rapid Increase in DARPP-32 Thr-34
Phosphorylation. We next investigated the mechanisms by which activation of ionotropic NMDA and AMPA glutamate receptors rapidly increased DARPP-32 Thr-34 phosphorylation in neostriatal slices. Because dopamine (14) and adenosine (15) , which stimulate DARPP-32 Thr-34 phosphorylation, are released in response to activation of NMDA and AMPA receptors, the effect of glutamate was examined in the presence of a dopamine D1 receptor antagonist, SCH23390, or an adenosine A 2A receptor antagonist, ZM241385. Neither SCH23390 nor ZM241385 affected the rapid increase in DARPP-32 Thr-34 phosphorylation induced by glutamate (compare Fig. 5 A and B with Fig. 1 A) .
Glutamate, by activating NMDA and AMPA receptors, stimulates the synthesis of NO in nNOS-and somatostatin-positive interneurons in the neostriatum (16) , and the synthesized NO regulates the function of medium spiny neurons (17) . DARPP-32 at Thr-34 also is an excellent substrate for PKG as well as PKA (18, 19) . We therefore examined the possible involvement of nNOS͞NO signaling in the glutamate-induced increase in DARPP-32 Thr-34 phosphorylation. Pretreatment of slices with an nNOS inhibitor, 7-NINA (10 M), or a soluble guanylyl cyclase inhibitor, ODQ (30 M), did not affect the basal level of phospho-Thr-34 DARPP-32 but abolished the glutamate-induced increase in DARPP-32 Thr-34 phosphorylation at 15 and 30 s of incubation (Fig. 5 C and D) . The results with 7-NINA and ODQ indicate that glutamate activates nNOS͞NO͞soluble guanylyl cyclase͞cGMP͞PKG signaling, leading to the rapid and transient phosphorylation of DARPP-32 at Thr-34.
Role of PPs in the Regulation of DARPP-32 Phosphorylation by
Glutamate. To investigate the involvement of PPs, the effect of glutamate was examined in the presence of a PP-2B inhibitor, cyclosporin A (10 M), or a PP-2A͞PP-1 inhibitor, okadaic acid (1 M), in neostriatal slices (20) . Pretreatment of neostriatal slices with cyclosporin A and okadaic acid increased the basal level of phospho-Thr-34 by 4.5-and 6.2-fold, respectively. In the presence of cyclosporin A, treatment with glutamate (5 mM) increased the level of phospho-Thr-34 DARPP-32 by 5.2-fold over the cyclosporin A-stimulated level at 30 s of incubation (Fig. 6A Upper) . Moreover, the stimulatory effect of glutamate was prolonged, compared with that in the absence of cyclosporin A. These results, together with those shown Fig. 1 , suggest that, following the rapid increase in Thr-34 phosphorylation through activation of nNOS͞ NO͞cGMP͞PKG signaling, glutamate, through activation of AMPA and NMDA receptors, stimulates the dephosphorylation of DARPP-32 at Thr-34 by PP-2B.
Okadaic acid abolished the glutamate-induced, rapid increase in DARPP-32 Thr-34 phosphorylation (Fig. 6B Upper) . The results indicate that the ability of the glutamate-activated nNOS͞NO͞ cGMP͞PKG signaling cascade to induce a rapid increase in Thr-34 phosphorylation requires active PP-2A and͞or PP-1.
Pretreatment of neostriatal slices with cyclosporin A did not affect the basal level of phospho-Thr-75 DARPP-32. In the presence of cyclosporin A, glutamate (5 mM) slightly increased the level of phospho-Thr-75 DARPP-32 at 15 and 30 s and decreased the level at 5 min of incubation (Fig. 6A Lower) . The small increase in Thr-75 phosphorylation at early time points is presumably mediated by an indirect effect of cyclosporin A, because phospho-Thr-75 DARPP-32 is not a substrate for PP-2B in vitro or in slices (5).
Pretreatment with okadaic acid increased the basal level of phospho-Thr-75 DARPP-32 by 8.1-fold and abolished any effect of glutamate (Fig. 6B Lower) . In agreement with a previous report (8) , these results suggest that the decrease in DARPP-32 Thr-75 phosphorylation is mediated through NMDA and AMPA receptordependent activation of PP-2A.
Regulation of nNOS Ser-847 Dephosphorylation by PP-2A.
It has been reported that, in vitro or in cells, nNOS is phosphorylated at Ser-847 by Ca 2ϩ ͞calmodulin-dependent protein kinase II and dephosphorylated by PP-2A (13, 21) . Furthermore, the phosphorylation of nNOS at Ser-847 results in the inhibition of nNOS activity (21) . We therefore studied the effects of PP-2A͞PP-1 inhibitors, okadaic acid and calyculin A, and a PP-2B inhibitor, cyclosporin A, on nNOS Ser-847 phosphorylation in neostriatal slices. We have previously reported that okadaic acid inhibits PP-2A͞PP-1 activity by 80%͞5% at 200 nM and by 95%͞35% at 1 M, and that calyculin A inhibits by 60%͞65% at 200 nM (20) . Treatment with calyculin A or okadaic acid, each at 200 nM, increased the level of phospho-Ser-847 nNOS by Ϸ11-fold, and treatment with okadaic acid at 1 M increased the level by 18-fold (Fig. 7) . Treatment with cyclosporin A did not affect nNOS Ser-847 phosphorylation. The results, showing the similar sensitivity to calyculin A and okadaic acid, suggest that nNOS at Ser-847 is mainly dephosphorylated by PP-2A in neostriatal slices.
Discussion
Glutamate is the major excitatory neurotransmitter in the brain and regulates multiple signal transduction cascades. Analysis of the regulation of DARPP-32 phosphorylation at Thr-34 (PKA-site) and Thr-75 (Cdk5-site) in neostriatal neurons revealed that glutamate, through activation of ionotropic (NMDA͞AMPA) and͞or mGlu receptors, modulates dopamine͞DARPP-32 signaling by activating five different signal transduction cascades ( 
Regulation of DARPP-32 Thr-34 Phosphorylation by Glutamate NMDA͞
AMPA and mGlu5 Receptor͞nNOS͞NO͞cGMP͞PKG Signaling. Glutamate induces a rapid and transient increase in DARPP-32 Thr-34 phosphorylation. The increase in Thr-34 phosphorylation is NMDA͞AMPA-and mGlu5-receptor-dependent and is abolished by inhibitors of nNOS and soluble guanylyl cyclase, indicating that glutamate activates nNOS in somatostatin-positive, GABAergic interneurons, where nNOS is expressed in the neostriatum (16) and stimulates the synthesis of NO. The NO diffuses into medium spiny neurons and activates soluble guanylyl cyclase, resulting in the formation of cGMP and activation of PKG. DARPP-32 Thr-34 is an excellent substrate for PKG as well as PKA (18, 19) , and therefore the activated PKG induces the phosphorylation of DARPP-32 at Thr-34. An increase in intracellular Ca 2ϩ , induced by Ca 2ϩ influx from extracellular space through activation of NMDA and AMPA receptors (22) and by Ca 2ϩ release from intracellular pools through activation of mGlu receptors (23) , has been shown to activate nNOS and stimulate the formation of NO. Activation of nNOS͞NO͞cGMP͞PKG signaling by glutamate and the subsequent increase in DARPP-32 Thr-34 phosphorylation likely play a physiological role, because both signaling components are required for the induction of long-term depression of excitatory synaptic potentials in the neostriatum (17, 24) .
The state of phosphorylation of nNOS at Ser-847 is regulated by the balance of phosphorylation by Ca 2ϩ ͞calmodulin-dependent protein kinase and dephosphorylation by PP-2A, and the phosphorylated form of nNOS at Ser-847 has lower catalytic activity (13, 21) . Our analysis revealed that dephosphorylation of nNOS at Ser-847 is mainly regulated by PP-2A in the neostriatum. In slices treated with okadaic acid (1 M), glutamate failed to stimulate nNOS͞NO͞cGMP͞PKG͞DARPP-32 signaling, possibly due to high phosphorylation of nNOS Ser-847 (by Ϸ20-fold over basal), supporting the inhibitory role of Ser-847 phosphorylation in nNOS activity.
NMDA͞AMPA Receptor͞Ca 2؉ ͞PP-2B Signaling. Activation of NMDA and AMPA receptors by glutamate results in an increase in intracellular Ca 2ϩ , leading to the stimulation of PP-2B. The dephosphorylation of DARPP-32 at Thr-34 by PP-2B counteracts the stimulatory effect of nNOS͞NO͞cGMP͞PKG signaling on DARPP-32 Thr-34 phosphorylation and moreover reduces DARPP-32 Thr-34 phosphorylation below basal levels. When PP-2B was inhibited by cyclosporin A, the stimulatory effect of nNOS͞NO͞cGMP͞PKG signaling was sustained for a longer time. (25) and by the interaction with calmodulin-binding proteins such as striatin and S͞G 2 nuclear autoantigen (26) . Because the phosphorylated form of DARPP-32 at Thr-75 inhibits PKA, the decrease in Thr-75 phosphorylation results in an increase in PKA activity by disinhibition (3). mGlu1 Receptor͞PLC Signaling. Group I mGlu receptors activate PLC␤ and stimulate the generation of inositol trisphosphate, leading to an increase in intracellular Ca 2ϩ . The increased intracellular Ca 2ϩ activates PP-2B, causing dephosphorylation of inhibitory autophosphorylation sites of CK1, which results in its activation (11) . Cdk5 is subsequently activated by CK1 (10) by an unknown mechanism and stimulates the phosphorylation of DARPP-32 at Thr-75. In the present study, we found that glutamate stimulated DARPP-32 Thr-75 phosphorylation by selectively activating mGlu1 receptor͞PLC␤ signaling.
In contrast with the regulation of Thr-34 phosphorylation by mGlu5 receptors, Thr-75 phosphorylation was regulated by mGlu1 receptors. The mechanisms of the selective regulation of Thr-34 and Thr-75 phosphorylation by mGlu5 and mGlu1 receptors, respectively, during the delayed phase are not clearly understood. Group I mGlu (mGlu1 and mGlu5) receptors preferentially activate a PLC signaling cascade but also are known to activate other signaling cascades (27) . mGlu5 receptors directly interact with adenosine A 2A receptors (28) and potentiate adenosine A 2A -receptor signaling in an ERK-dependent manner in indirect pathway neurons (9) . Furthermore, functions of mGlu1 and mGlu5 receptors are differentially regulated by PKC, G protein-coupled receptor kinase, regulator of G protein signaling, and Src-family protein tyrosine kinase (27, 29) . Signaling cascades, differentially activated by mGlu1 or mGlu5 receptors, might be factors in the selective regulation of DARPP-32 at Thr-34 and Thr-75.
In summary, glutamate, through regulation of the activity of at least five signaling pathways with distinct time dependencies, contributes to a complex pattern of phosphorylation of Thr-34 and Thr-75 DARPP-32. Phosphorylation of these two sites, through modulation of PP-1 and PKA activities, controls in a coordinated fashion the state of phosphorylation of a vast number of neuronal phosphoproteins and, thereby, many physiological parameters. These studies highlight the role of DARPP-32 in the interaction of dopamine and glutamate in the neostriatum under normal conditions. Future studies of these pathways also should result in a greater understanding of pathophysiological conditions such as Parkinson's disease and schizophrenia. It will be important in the future to elucidate the precise patterns of glutamate-induced signaling cascades in the two types of medium spiny neurons, the direct͞striatonigral and the indirect͞striatopallidal pathway neurons.
